[Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly].
Consensus statement of the Polish Society of Endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. It is suggested to administer depot somatostatin analog (Octreotide LAR at the dose 20 mg and then 30 mg or equivalent doses of Lanreotide Autogel 90/120 mg every 4 weeks) in order to normalize or suppress to a maximal extent GH and IGF-1 concentrations. The period of therapy in case of microadenoma would be at least 3 months (targets: biochemical improvement, reduced risk of disease's complications, perioperative risk reduction, inhibition of tumor growth). The period of therapy in case of macroadenoma would be at least 6 months, until maximal possible reduction of GH and IGF-1 concentrations (targets: tumor shrinkage, biochemical improvement, reduced risk of disease's complications, perioperative risk reduction). Using an uniform approach in a group, as numerous as possible, of treated patients would allow objective evaluation of long-term efficacy of the treatment.
Bolanowski
Marek
M
Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Akademia Medyczna, Wrocław. bolan@endo.am.wroc.pl
Bar-Andziak
Ewa
E
Kos-Kudła
Beata
B
Krzyzanowska-Swiniarska
Barbara
B
Lewiński
Andrzej
A
Lomna-Bogdanov
Elzbieta
E
Milewicz
Andrzej
A
Sowiński
Jerzy
J
Zgliczyński
Wojciech
W
D000172:Acromegaly / Q000188:drug therapy* / Q000601:surgery; D006728:Hormones / Q000627:therapeutic use*; D019382:Human Growth Hormone; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D006728:Hormones; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide